XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
XOMA (XOMA) Target Cut to $9 at Jefferies
March 5, 2014 8:37 AM ESTJefferies analyst Biren Amin cut is price target on XOMA, Ltd. (NASDAQ: XOMA) from $11 to $9 after the company announced that the gevokizumab program for erosive osteoarthritis of the hand (EOA) is being discontinued after gevokizumab failed to demonstrate benefit in the two PII trials. The... More
XOMA (XOMA) Sinks Over 15% on Trade Resumption
March 4, 2014 5:29 PM ESTXOMA (NASDAQ: XOMA) has resumed trading and is down 15.2% after reporting that it will not purse gevokizumab development for the broad EOA indication. In addition, XOMA reported a large fourth quarter loss.... More
XOMA Ltd (XOMA) Posts Q4 GAAP Loss of 55c/Share
March 4, 2014 5:00 PM ESTXOMA Ltd (NASDAQ: XOMA) reported Q4 EPS of ($0.55), which may not compare with the analyst estimate of ($0.19). Revenue for the quarter came in at $8.45 million versus the consensus estimate of $7.92 million.
Of the $0.55 per share loss, $35.3 million, or $0.37 per share, was related directly to the... More
